Cytokinetics CYTK Fair Value Of Stock Issued For Convertible Note
Discontinued — last reported Q4 '25
Fair Value Of Stock Issued For Convertible Note at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:FairValueOfStockIssuedForConvertibleNote.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's fair value of stock issued for convertible note.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's fair value of stock issued for convertible note?
- Cytokinetics (CYTK) reported fair value of stock issued for convertible note of $26.98M in Q4 2025.
- What is the long-term trend for Cytokinetics's fair value of stock issued for convertible note?
- Over 2 years (2022 to 2025), Cytokinetics's fair value of stock issued for convertible note has grown at a -41.7% compound annual growth rate (CAGR), from $317.12M to $107.92M.
- What does fair value of stock issued for convertible note mean?
- The value of company stock given to lenders to pay off convertible debt.
- How do you interpret fair value of stock issued for convertible note?
- High values indicate significant debt-to-equity conversion, which reduces debt burden but results in shareholder dilution.
- How does fair value of stock issued for convertible note compare across companies?
- Specific to companies utilizing convertible debt instruments; common in growth-stage biotech and technology sectors.